Standard and emerging therapies for metastatic differentiated thyroid cancer

Oncologist

Volumn 15, Issue 2, 2010, Pages 146-156

  O'Neill, Christine J ^a   Oucharek, Jennifer ^a   Learoyd, Diana ^b   Sidhu, Stan B ^a,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Iodine radioiosotopes; Neoplasm metastasis; Protein kinase inhibitors; Proto oncogene proteins B Raf; Thyroid neoplasms

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; AXITINIB; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CAPECITABINE; CELECOXIB; CISPLATIN; DOXORUBICIN; E 7080; FLUORODEOXYGLUCOSE F 18; GEFITINIB; IROFULVEN; LENALIDOMIDE; MOTESANIB; PACLITAXEL; PEMETREXED; RADIOACTIVE IODINE; ROMIDEPSIN; ROSIGLITAZONE; SORAFENIB; SUNITINIB; TANESPIMYCIN; THALIDOMIDE; THYROXINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VORINOSTAT;

ADVANCED CANCER; BONE ATROPHY; BONE METASTASIS; BRAIN METASTASIS; CANCER CELL DESTRUCTION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; DIFFERENTIATED THYROID CANCER; DISTANT METASTASIS; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG FATALITY; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG UPTAKE; DRUG WITHDRAWAL; EXTERNAL BEAM RADIOTHERAPY; GENE MUTATION; GENE TARGETING; HEART ATRIUM FIBRILLATION; HUMAN; LACRIMAL GLAND DISEASE; LEUKEMIA; LIVER FAILURE; LUNG FIBROSIS; LUNG METASTASIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN TARGETING; REVIEW; SALIVARY GLAND DISEASE; SIDE EFFECT; SUBTOTAL THYROIDECTOMY; THERAPY EFFECT; THYROID CANCER; TUMOR DIFFERENTIATION; UNSPECIFIED SIDE EFFECT;

HUMANS; NEOPLASM METASTASIS; THYROID NEOPLASMS;

EID: 77649155708     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2009-0190     Document Type: Review

References (126)

1. Sherman SI. Thyroid carcinoma. Lancet 2003;361:501-511.
2. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006;295:2164-2167.
3. Stavrou EP, Baker DF, McElroy HJ et al. Thyroid Cancer in New South Wales. Sydney, Australia: Cancer Institute NSW, 2008:1-73.
4. Leenhardt L, Grosclaude P, Chérié-Challine L et al. Increased incidence of thyroid carcinoma in France: A true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee. Thyroid 2004;14:1056-1060.
5. Cooper DS, Doherty GM, Haugen BR et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006;16:109-142.
6. British Thyroid Association Royal College of Physicians. Perros P, ed. Guidelines for the Management of Thyroid Cancer, Second Edition. Report of the Thyroid Cancer Guidelines Update Group. London: London Royal College of Physicians, 2007:1-92.
7. Eustatia-Rutten CF, Corssmit EP, Biermasz NR et al. Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab 2006; 91:313-319.
8. Durante C, Haddy N, Baudin E et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006; 91:2892-2289.
9. Showalter TN, Siegel BA, Moley JF et al. Prognostic factors in patients with well-differentiated thyroid cancer presenting with pulmonary metastasis. Cancer Biother Radiopharm 2008;23:655-659.
10. Zanotti-Fregonara P, Hindié E, Faugeron I et al. Update on the diagnosis and therapy of distant metastases of differentiated thyroid carcinoma. Minerva Endocrinol 2008;33:313-327.
11. Sampson E, Brierley JD, Le LW et al. Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis. Cancer 2007;110:1451-1456.
12. Casara D, Rubello D, Saladini G et al. Different features of pulmonary metastases in differentiated thyroid cancer: Natural history and multivariate statistical analysis of prognostic variables. J Nucl Med 1993;34: 1626-1631.
13. Shimaoka K, Schoenfeld DA, DeWys WD et al. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 1985;56:2155-2160.
14. Williams SD, Birch R, Einhorn LH. Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: A Southeastern Cancer Study Group trial. Cancer Treat Rep 1986;70:405-407.
15. Tsang RW, Brierley JD, Simpson WJ et al. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma. Cancer 1998;82:375-388.
16. Baudin E, Schlumberger M. New therapeutic approaches for metastatic thyroid carcinoma. Lancet Oncol 2007;8:148-156.
17. Xing M. Recent advances in molecular biology of thyroid cancer and their clinical implications. Otolaryngol Clin North Am 2008;41:1135-1146.
18. Tuttle RM. Novel therapeutic options for aggressive thyroid cancer: Integrating information from the recent clinical trials into clinical practice. Clinical Thryoidology [serial online] 2009;21:3-7. Available at http://thyroid.org/professionals/publications/clinthy/volume21/issue1/ clinthy-v211-3-7.pdf, accessed June 22, 2009.
19. Fatourechi V, Hay ID, Mullan BP et al. Are posttherapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer? Thyroid 2000;10:573-577.
20. Sherman SI, Tielens ET, Sostre S et al. Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma. J Clin Endocrinol Metab 1994;78:629-634.
21. Souza Rosário PW, Barroso AL, Rezende LL et al. Post I-131 therapy scanning in patients with thyroid carcinoma metastases: An unnecessary cost or a relevant contribution? Clin Nucl Med 2004;29:795-798.
22. Toubert ME, Hindie E, Rampin L et al. Distant metastases of differentiated thyroid cancer: Diagnosis, treatment and outcome. Nucl Med Rev Cent East Eur 2007;10:106-109.
23. Ronga G, Filesi M, Montesano T et al. Lung metastases from differentiated thyroid carcinoma. A 40 years' experience. Q J Nucl Med Mol Imaging 2004;48:12-19.
24. Shoup M, Stojadinovic A, Nissan A et al. Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma. J Am Coll Surg 2003;197:191-197.
25. Schlumberger M, Challeton C, De Vathaire F et al. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med 1996;37:598-605.
26. Lin JD, Chao TC, Chou SC et al. Papillary thyroid carcinomas with lung metastases. Thyroid 2004;14:1091-1096.
27. Bernier MO, Leenhardt L, Hoang C et al. Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas. J Clin Endocrinol Metab 2001;86:1568-1573.
28. Dinneen SF, Valimaki MJ, Bergstralh EJ et al. Distant metastases in papillary thyroid carcinoma: 100 cases observed at one institution during 5 decades. J Clin Endocrinol Metab 1995;80:2041-2045.
29. Ilgan S, Karacalioglu AO, PabuscuYet al. Iodine-131 treatment and high-resolution CT: Results in patients with lung metastases from differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging 2004;31:825-830.
30. Hindié E, Mellière D, Lange F et al. Functioning pulmonary metastases of thyroid cancer: Does radioiodine influence the prognosis? Eur J Nucl Med Mol Imaging 2003;30:974-981.
31. Muresan MM, Olivier P, Leclère J et al. Bone metastases from differentiated thyroid carcinoma. Endocr Relat Cancer 2008;15:37-49.
32. Hindié E, Zanotti-Fregonara P, Keller I et al. Bone metastases of differentiated thyroid cancer: Impact of early 131I-based detection on outcome. Endocr Relat Cancer 2007;14:799-807.
33. Zettinig G, Fueger BJ, Passler C et al. Long-term follow-up of patients with bone metastases from differentiated thyroid carcinoma - surgery or conventional therapy? Clin Endocrinol (Oxf) 2002;56:377-382.
34. Mihailovic J, Stefanovic L, MalesevicMet al. The importance of age over radioiodine avidity as a prognostic factor in differentiated thyroid carcinoma with distant metastases. Thyroid 2009;19:227-232.
35. Mihailovic JM, Stefanovic LJ, Malesevic MD et al. Metastatic differentiated thyroid carcinoma: Clinical management and outcome of disease in patients with initial and late distant metastases. Nucl Med Commun 2009; 30:558-564.
36. Haq M, Harmer C. Differentiated thyroid carcinoma with distant metastases at presentation: Prognostic factors and outcome. Clin Endocrinol (Oxf) 2005;63:87-93.
37. Rubino C, de Vathaire F, Dottorini ME et al. Second primary malignancies in thyroid cancer patients. Br J Cancer 2003;89:1638-1644.
38. Brown AP, Chen J, Hitchcock YJ et al. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab 2008;93:504-515.
39. Sawka AM, Thabane L, Parlea L et al. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: A systematic review and meta-analysis. Thyroid 2009;19:451-457.
40. 131I scintigraphy in the detection of metastatic thyroid cancer. Clin Imaging 2008;32:32-37.
41. 18F- fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. Thyroid 2001;11:1169-1175.
42. Ma C, Kuang A, Xie J. Radioiodine therapy for differentiated thyroid carcinoma with thyroglobulin positive and radioactive iodine negative metastases. Cochrane Database Syst Rev 2009;(1):CD006988.
43. Pacini F, Lippi F, Formica N et al. Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. J Nucl Med 1987;28:1888-1891.
44. Pineda JD, Lee T, Ain K et al. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab 1995;80:1488-1492.
45. 131I therapy for elevated thyroglobulin levels. Thyroid 1997;7:273-276.
46. Fatourechi V, Hay ID, Javedan H et al. Lack of impact of radioiodine therapy in tg-positive, diagnostic whole-body scan-negative patients with follicular cell-derived thyroid cancer. J Clin Endocrinol Metab 2002;87: 1521-1526.
47. Bukowski RM, Brown L, Weick JK et al. Combination chemotherapy of metastatic thyroid cancer. Phase II study. Am J Clin Oncol 1983;6: 579-581.
48. Gottlieb JA, Hill CS Jr. Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients. N Engl J Med 1974;290:193-197.
49. Gottlieb JA, Hill CS Jr, Ibanez ML et al. Chemotherapy of thyroid cancer. An evaluation of experience with 37 patients. Cancer 1972;30:848-853.
50. Matuszczyk A, Petersenn S, Bockisch A et al. Chemotherapy with doxorubicin in progressive medullary and thyroid carcinoma of the follicular epithelium. Horm Metab Res 2008;40:210-213.
51. National Institute of Health. Clinical Trials 2009. Available at http://clinicaltrials.gov/ct2/results?cond=Thyroid+Neoplasms, accessed June 29, 2009.
52. Biondi B, Filetti S, Schlumberger M. Thyroid-hormone therapy and thyroid cancer: A reassessment. Nat Clin Pract Endocrinol Metab 2005;1:32-40.
53. Jonklaas J, Sarlis NJ, Litofsky D et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 2006;16: 1229-1242.
54. Brown RL. Standard and emerging therapeutic approaches for thyroid malignancies. Semin Oncol 2008;35:298-308.
55. Azrif M, Slevin NJ, Sykes AJ et al. Patterns of relapse following radiotherapy for differentiated thyroid cancer: Implication for target volume delineation. Radiother Oncol 2008;89:105-113.
56. Terezakis SA, Lee KS, Ghossein RA et al. Role of external beam radiotherapy in patients with advanced or recurrent nonanaplastic thyroid cancer: Memorial Sloan-Kettering Cancer Center experience. Int J Radiat Oncol Biol Phys 2009;73:795-801.
57. Brierley JD, Tsang RW. External beam radiation therapy for thyroid cancer. Endocrinol Metab Clin North Am 2008;37:497-509.
58. Tubiana M, Haddad E, Schlumberger M et al. External radiotherapy in thyroid cancers. Cancer 1985;55:2062-2071.
59. Chiu AC, Delpassand ES, Sherman SI. Prognosis and treatment of brain metastases in thyroid carcinoma. J Clin Endocrinol Metab 1997;82:3637-3642.
60. McWilliams RR, Giannini C, Hay ID et al. Management of brain metastases from thyroid carcinoma: A study of 16 pathologically confirmed cases over 25 years. Cancer 2003;98:356-362.
61. Tokuhashi Y, Matsuzaki H, Toriyama S et al. Scoring system for the preoperative evaluation of metastatic spine tumor prognosis. Spine 1990;15: 1110-1113.
62. Kasai Y, Kawakita E, Uchida A. Clinical profile of long-term survivors of breast or thyroid cancer with metastatic spinal tumours. Int Orthop 2007; 31:171-175.
63. Protopapas AD, Nicholson AG, Vini L et al. Thoracic metastasectomy in thyroid malignancies. Ann Thorac Surg 2001;72:1906-1908.
64. Porterfield JR, Cassivi SD, Wigle DA et al. Thoracic metastasectomy for thyroid malignancies. Eur J Cardiothorac Surg 2009;36:155-158.
65. Sherman SI. Early clinical studies of novel therapies for thyroid cancers. Endocrinol Metab Clin North Am 2008;37:511-524.
66. Fagin JA, Mitsiades N. Molecular pathology of thyroid cancer: Diagnostic and clinical implications. Best Pract Res Clin Endocrinol Metab 2008;22: 955-969.
67. Sobrinho-Simoes M, Máximo V, Rocha AS et al. Intragenic mutations in thyroid cancer. Endocrinol Metab Clin North Am 2008;37:333-362.
68. Riesco-Eizaguirre G, Santisteban P. New insights in thyroid follicular cell biology and its impact in thyroid cancer therapy. Endocr Relat Cancer 2007;14:957-977.
69. Nikiforova MN, Nikiforov YE. Molecular genetics of thyroid cancer: Implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn 2008;8:83-95.
70. Xing M. BRAF mutation in papillary thyroid cancer: Pathogenic role, molecular bases, and clinical implications. Endocr Rev 2007;28:742-762.
71. Knauf JA, Fagin JA. Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets. Curr Opin Cell Biol 2009;21:296-303.
72. Elisei R, Ugolini C, Viola D et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: A 15-year median follow-up study. J Clin Endocrinol Metab 2008;93:3943-3949.
73. Xing M, Westra WH, Tufano RP et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005;90:6373-6379.
74. Riesco-Eizaguirre G, Gutiérrez-Martínez P, García-Cabezas MA et al. The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I-targeting to the membrane. Endocr Relat Cancer 2006;13:257-269.
75. Durante C, Puxeddu E, Ferretti E et al. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab 2007;92:2840-2843.
76. Romei C, Ciampi R, Faviana P et al. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer. Endocr Relat Cancer 2008;15:511-520.
77. Liu Z, Hou P, Ji M et al. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab 2008;93:3106-3116.
78. Santarpia L, El-Naggar AK, Cote GJ et al. Phosphatidylinositol 3-kinase/Akt and Ras/Raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. J Clin Endocrinol Metab 2008;93:278-284.
79. Kundra P, Burman KD. Thyroid cancer molecular signaling pathways and use of targeted therapy. Endocrinol Metab Clin North Am 2007;36:839-853.
80. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92: 205-216.
81. Ain KB, Lee C, Williams KD. Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas. Thyroid 2007;17:663-670.
82. Mrozek E, Kloos RT, RingelMDet al. Phase II study of celecoxib in metastatic differentiated thyroid carcinoma. J Clin Endocrinol Metab 2006; 91:2201-2204.
83. Woyach JA, Kloos RT, Ringel MD et al. Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma. J Clin Endocrinol Metab 2009;94: 164-170.
84. Sherman SI, Wirth LJ, Droz JP et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 2008;359:31-42.
85. Cohen EE, Rosen LS, Vokes EE et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study. J Clin Oncol 2008;26:4708-4713.
86. Gupta-Abramson V, Troxel AB, Nellore A et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008;26:4714-4719.
87. Pennell NA, Daniels GH, Haddad RI et al. A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid 2008;18:317-323.
88. Heemstra KA, Hoftijzer HC, Corssmit EPM et al. Sorafenib in patients with progressive differentiated thyroid carcinoma: A phase 2 trial [abstract OR21-4]. Presented at the Endocrine Society Annual Meeting, June 10-13, 2009.
89. Ain KB, Lee C, Holbrook JM et al. Phase II study of lenalidomide in distantly metastatic rapidly progressive, and radioiodine-unresponsive thyroid carcinomas: Preliminary results. J Clin Oncol 2008;26(15 suppl): 6027.
90. Brierley JD, Tsang RW, Glisson MS et al. Bortezomib in patietns with metastatic differentiated thyroid cancer: Preliminary results of a multicentre phase II study. American Thyroid Association meeting, Phoenix, October 2006. Thyroid 2006;16:857.
91. Kloos RT, Ringel MD, Knopp MV et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009;27:1675-1684.
92. Castellone MD, Carlomagno F, Salvatore G et al. Receptor tyrosine kinase inhibitors in thyroid cancer. Best Pract Res Clin Endocrinol Metab 2008; 22:1023-1038.
93. Polverino A, Coxon A, Starnes C et al. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res 2006;66: 8715-8721.
94. Stommel JM, Kimmelman AC, Ying H et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007;318:287-290.
95. Dawson SJ, Conus NM, Toner GC et al. Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma. Anticancer Drugs 2008;19:547-552.
96. Carlomagno F, Anaganti S, Guida T et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 2006;98:326-334.
97. Carlomagno F, Vitagliano D, Guida T et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 2002;62:7284-7290.
98. Lopez JP, Wang-Rodriguez J, Chang CY et al. Gefitinib (Iressa) potentiates the effect of ionizing radiation in thyroid cancer cell lines. Laryngoscope 2008;118:1372-1376.
99. Lopez JP, Wang-Rodriguez J, Chang C et al. Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines. Arch Otolaryngol Head Neck Surg 2007;133:1022-1027.
100. Rinehart J, Adjei AA, Lorusso PM et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 2004;22:4456-4462.
101. Lorusso PM, Adjei AA, Varterasian M et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 2005;23:5281-5293.
102. Henderson YC, Ahn SH, Clayman GL. Inhibition of the growth of papillary thyroid carcinoma cells by CI-1040. Arch Otolaryngol Head Neck Surg 2009;135:347-354.
103. Liu D, Xing M. Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathways. Thyroid 2008;18:853-864.
104. Sodré AK, Rubio IG, Galrao AL et al. Association of low sodium-iodide symporter messenger ribonucleic acid expression in malignant thyroid nodules with increased intracellular protein staining. J Clin Endocrinol Metab 2008;93:4141-4145.
105. - symporter (NIS) research in the thyroid and beyond. Mol Cell Endocrinol 2003;213:59-70.
106. Spitzweg C, Morris JC. The sodium iodide symporter: Its pathophysiological and therapeutic implications. Clin Endocrinol (Oxf) 2002;57:559-574.
107. Oler G, Cerutti JM. High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas: Correlation with more aggressive phenotype and decreased expression of iodide-metabolizing genes. Cancer 2009;115:972-980.
108. 131I therapy of metastatic, well differentiated thyroid carcinoma. J Clin Endocrinol Metab 1999;84:912-916.
109. Pons F, Carrió I, Estorch M et al. Lithium as an adjuvant of iodine-131 uptake when treating patients with well-differentiated thyroid carcinoma. Clin Nucl Med 1987;12:644-647.
110. Liu YY, van der Pluijm G, Karperien M et al. Lithium as adjuvant to radioiodine therapy in differentiated thyroid carcinoma: Clinical and in vitro studies. Clin Endocrinol (Oxf) 2006;64:617-624.
111. Kurebayashi J, Tanaka K, Otsuki T et al. All-trans-retinoic acid modulates expression levels of thyroglobulin and cytokines in a new human poorly differentiated papillary thyroid carcinoma cell line, KTC-1. J Clin Endocrinol Metab 2000;85:2889-2896.
112. Schmutzler C, Brtko J, Bienert K et al. Effects of retinoids and role of retinoic acid receptors in human thyroid carcinomas and cell lines derived therefrom. Exp Clin Endocrinol Diabetes 1996;104(suppl 4):16-19.
113. Grn̈wald F, Menzel C, Bender H et al. Redifferentiation therapy-induced radioiodine uptake in thyroid cancer. J Nucl Med 1998;39:1903-1906.
114. Simon D, Körber C, Krausch M et al. Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: Final results of a pilot study. Eur J Nucl Med Mol Imaging 2002;29:775-782.
115. Grn̈ing T, Tiepolt C, Zöphel K et al. Retinoic acid for redifferentiation of thyroid cancer - does it hold its promise? Eur J Endocrinol 2003;148: 395-402.
116. Courbon F, Zerdoud S, Bastie D et al. Defective efficacy of retinoic acid treatment in patients with metastatic thyroid carcinoma. Thyroid 2006;16: 1025-1031.
117. Liu YY, Stokkel MP, Pereira AM et al. Bexarotene increases uptake of radioiodide in metastases of differentiated thyroid carcinoma. Eur J Endocrinol 2006;154:525-531.
118. Zhang Y, Jia S, Liu Y et al. A clinical study of all-trans-retinoid- induced differentiation therapy of advanced thyroid cancer. Nucl Med Commun 2007;28:251-255.
119. Martelli ML, Iuliano R, Le Pera I et al. Inhibitory effects of peroxisome proliferator-activated receptor gamma on thyroid carcinoma cell growth. J Clin Endocrinol Metab 2002;87:4728-4735.
120. Kebebew E, Peng M, Reiff E et al. A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer. Surgery 2006;140:960-966; discussion 966-967.
121. Tepmongkol S, Keelawat S, Honsawek S et al. Rosiglitazone effect on radioiodine uptake in thyroid carcinoma patients with high thyroglobulin but negative total body scan: A correlation with the expression of peroxisome proliferator-activated receptor-gamma. Thyroid 2008;18:697-704.
122. Mandell RB, Mandell LZ, Link CJ Jr. Radioisotope concentrator gene therapy using the sodium/iodide symporter gene. Cancer Res 1999;59: 661-668.
123. Boland A, Ricard M, Opolon P et al. Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy. Cancer Res 2000;60:3484-3492.
124. Spitzweg C, Morris JC. Gene therapy for thyroid cancer: Current status and future prospects. Thyroid 2004;14:424-434.
125. - symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. J Clin Endocrinol Metab 2001;86:3430-3435.
126. Puppin C, D'Aurizio F, D'Elia AV et al. Effects of histone acetylation on sodium iodide symporter promoter and expression of thyroid-specific transcription factors. Endocrinology 2005;146:3967-3974.